Eftilagimod alfa Medicine 04 June 2026 Extended indication Eftilagimod alfa in combination with paclitaxel for first line or later treatment of metastatic HR-positive/negative, HER2-negative/low and triple-negative breast cancer in adults and elderly Therapeutic value Total cost Registration phase Clinical trials Product Active substance Eftilagimod alfa Domain Oncology Reason of inclusion New medicine (specialité) Main indication Breast cancer Extended indication Eftilagimod alfa in combination with paclitaxel for first line or later treatment of metastatic HR-positive/negative, HER2-negative/low and triple-negative breast cancer in adults and elderly Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Immutep Portfolio holder Immutep Mechanism of action Other, see general comments Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks ACP-activator. Fabrikant: Immutep Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP Submission date January 2027 Expected Registration February 2028 Orphan drug Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Er zijn nog geen resultaten bekend. Duration of treatment Frequency of administration Dosage per administration References NCT05747794 (AIPAC-003) Additional remarks Expected patient volume per year Patient volume < 950 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR 2022 Additional remarks In 2022 waren er 950 diagnoses stadium IV borstkanker. Expected cost per patient per year Cost References Additional remarks Er is nog niets bekend over de mogelijke prijs. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks